Cystatin C assay industry size is projected to expand at over 7.7% CAGR from 2024 to 2032. The rising prevalence of chronic kidney diseases (CKDs) globally, coupled with the aging population is driving the demand for accurate and early diagnostic tools, such as cystatin C assays.

Of late, there has been growing awareness about the limitations of traditional biomarkers like creatinine in detecting early-stage kidney dysfunctions. The increasing technological advancements are leading to the development of more sensitive and specific assays. For instance, in August 2022, Bloom Diagnostics, a Swiss MedTech company, launched Bloom Kidney Test, designed for quantifying cystatin C in whole blood. The surging emphasis on preventive healthcare and the integration of innovative diagnostic solutions in healthcare systems will also fuel the market expansion.

The cystatin C assay market is segregated into product, sample type, method, application, end-use, and region.

In terms of product, the industry value from the reagents segment is estimated to rise at 7.7% CAGR from 2024 to 2032, owing to the increasing demand for reliable diagnostic tools due to the rising prevalence of chronic kidney diseases. The ongoing advancements in reagent technology is leading to enhanced accuracy and sensitivity. Additionally, the growing awareness of the limitations of traditional biomarkers will boost the segment growth.

The urine sample segment of the cystatin C assay market is estimated to depict 7.5% CAGR between 2024 and 2032. The growth can be attributed to the heightened demand for precise kidney function assessment and the increasing awareness of the advantages of urine-based cystatin C testing. Moreover, the higher incidences of renal disorders will further drive the adoption of urine sampling.

Regionally, the Europe cystatin C assay industry size is projected to expand at 7.8% CAGR from 2024 to 2032. The growth can be attributed to the surge in chronic kidney disease cases, rapidly aging population, and the increasing adoption of advanced diagnostic technologies. Additionally, the high emphasis on healthcare infrastructure development and preventive medicine will drive the regional market expansion.